Click on a filter below to refine your search. Remove a filter to broaden your search.
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Immediate and lasting reductions were seen in the share of patients receiving hospice care with the Alzheimer’s disease and related dementia code.
In some cases, cognitive impairment is reversible, but up to one-third of individuals with stroke develop dementia within five years.
The cost of a 30-day readmission and total 30-day episode costs were higher for people living with Alzheimer’s disease and related dementias.
Risk for death, unplanned hospital admission significantly lower for those taking AChEIs only or taking AChEIs and memantine
Overall accuracy of two-step protocol including two-item screen and 3-minute diagnostic assessment was 89%, 87% for nurses, doctors.
A higher value on an oral glucose tolerance test at baseline was linked to worse performance and greater decline in a word-list delayed recall test.
The findings show a 40% higher risk among housing-insecure veterans.
Enrollees with Alzheimer’s disease and related dementias had increased adjusted mortality, especially for Asian, Black and Hispanic populations.
The findings were seen in older hospitalized patients with advanced chronic obstructive pulmonary disease, dementia or kidney failure.